CA3073646A1 - Production of flu vaccine in myceliophthora thermophila - Google Patents

Production of flu vaccine in myceliophthora thermophila Download PDF

Info

Publication number
CA3073646A1
CA3073646A1 CA3073646A CA3073646A CA3073646A1 CA 3073646 A1 CA3073646 A1 CA 3073646A1 CA 3073646 A CA3073646 A CA 3073646A CA 3073646 A CA3073646 A CA 3073646A CA 3073646 A1 CA3073646 A1 CA 3073646A1
Authority
CA
Canada
Prior art keywords
influenza virus
influenza
surface protein
virus surface
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3073646A
Other languages
English (en)
French (fr)
Inventor
Mark EMALFARB
Teunis Cornelis Verwoerd
Mark R. Alfenito
Mark Baer
Isabelle Legastelois
Marie-Pierre KAZEK
Marie-Clotilde BERNARD
Jean Dubayle
Richard KENSINGER
Original Assignee
Dyadic International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyadic International Inc filed Critical Dyadic International Inc
Publication of CA3073646A1 publication Critical patent/CA3073646A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungi isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3073646A 2017-08-21 2018-08-09 Production of flu vaccine in myceliophthora thermophila Abandoned CA3073646A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547885P 2017-08-21 2017-08-21
US62/547,885 2017-08-21
PCT/IB2018/056003 WO2019038623A1 (en) 2017-08-21 2018-08-09 PRODUCTION OF AN INFLUENZA VACCINE IN MYCELIOPHTHORA THERMOPHILA

Publications (1)

Publication Number Publication Date
CA3073646A1 true CA3073646A1 (en) 2019-02-28

Family

ID=65438455

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073646A Abandoned CA3073646A1 (en) 2017-08-21 2018-08-09 Production of flu vaccine in myceliophthora thermophila

Country Status (9)

Country Link
US (2) US11738080B2 (enExample)
EP (1) EP3672630A4 (enExample)
JP (1) JP2020533966A (enExample)
KR (1) KR20200090143A (enExample)
CN (1) CN111315408A (enExample)
AU (1) AU2018319501A1 (enExample)
CA (1) CA3073646A1 (enExample)
IL (1) IL272568A (enExample)
WO (1) WO2019038623A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230313121A1 (en) * 2020-05-14 2023-10-05 Dyadic International (Usa), Inc. Modified filamentous fungi for production of exogenous proteins
CN117377752A (zh) * 2021-03-11 2024-01-09 二进国际(美国)有限公司 用于生产具有减少的或不含n-连接的糖基化的外源蛋白的遗传修饰的丝状真菌
CN119836469A (zh) 2022-05-20 2025-04-15 辉宝动物保健公司 使用真菌构建体产生病毒蛋白抗原

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE245199T1 (de) 1994-05-20 2003-08-15 Sinai School Medicine Behandlung von influenzavirus-infektion unter verwendung von antiviralen acylierung/palmitylierung von hemagglutinin hemmen
ATE286136T1 (de) 1998-10-06 2005-01-15 Mark Aaron Emalfarb Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
CN100420753C (zh) 2000-04-13 2008-09-24 马克·阿龙·埃马尔法尔布 丝状真菌领域的新的表达调节序列和表达产物
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
JP5060958B2 (ja) 2004-10-15 2012-10-31 イントレキソン コーポレーション 多価組換え抗原のコンビナトリアルベースの生産のための方法および組成物
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
WO2008073490A1 (en) * 2006-12-12 2008-06-19 Carrington Laboratories Inc., Purification of influenza viral antigens
DK3421597T3 (da) 2009-03-16 2021-01-25 Danisco Us Inc System til chrysosporium lucknowense-proteinfremstilling
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
WO2010150982A2 (ko) 2009-06-23 2010-12-29 한밭대학교 산학협력단 안전성이 뛰어난 인플루엔자 바이러스 백신용 재조합 헤마글루티닌 단백질 및 이를 함유하는 생분해성 ｐｌｇａ 미립자의 제조 방법
CA2787974A1 (en) 2010-01-24 2011-07-28 Biological Mimetics, Inc. Immunogenic influenza composition
US20150087028A1 (en) * 2012-03-12 2015-03-26 Codexis, Inc. Cbh1a variants
US20130315955A1 (en) 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
EP3233924B1 (en) 2014-12-19 2019-05-15 Sanofi Pasteur Multimerization of recombinant protein by fusion to a sequence from lamprey
JP2019503168A (ja) 2015-12-02 2019-02-07 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Ｃｌｒ２活性が低減した糸状菌においてタンパク質を生産する方法

Also Published As

Publication number Publication date
KR20200090143A (ko) 2020-07-28
EP3672630A1 (en) 2020-07-01
JP2020533966A (ja) 2020-11-26
IL272568A (en) 2020-03-31
US20230346913A1 (en) 2023-11-02
US20200215183A1 (en) 2020-07-09
CN111315408A (zh) 2020-06-19
EP3672630A4 (en) 2021-06-02
AU2018319501A1 (en) 2020-04-02
US11738080B2 (en) 2023-08-29
WO2019038623A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
US20230346913A1 (en) Production of flu vaccine in myceliophthora thermophila
CA2730171C (en) Soluble recombinant influenza antigens
CN101883856B (zh) 包含植物内生产之血凝素的流感病毒样颗粒(vlp)
CN102165062B (zh) 新的流感病毒免疫表位
EP3160501B1 (en) Influenza virus hemagglutinin protein as a vaccine antigen
Wang et al. Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris
US20100129401A1 (en) Functional Influenza Virus Like Particles (VLPs)
Athmaram et al. Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice
CN110272473A (zh) 甲型流感通用型病毒样颗粒及其制备方法和应用
CN112153981A (zh) 产生包含神经氨酸酶的广泛保护性疫苗组合物的方法
Krammer et al. Swine‐origin pandemic H1N1 influenza virus‐like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice
Spitsin et al. Immunological assessment of plant-derived avian flu H5/HA1 variants
AU2017225820B2 (en) Novel influenza antigens
Qian et al. Secretion of truncated recombinant rabies virus glycoprotein with preserved antigenic properties using a co-expression system in Hansenula polymorpha
CN116589596A (zh) 甲型流感na多肽广谱免疫原及其序贯免疫方法
EP3083660B1 (en) Method of influenza antigen production
WO2023018817A1 (en) Truncated influenza neuraminidase and methods of using the same
AU2021416258A1 (en) Surface displayed endoglycosidases
WO2022147265A1 (en) Surface displayed endoglycosidases
AU2015202195A1 (en) New influenza virus immunizing epitope
Kim et al. In planta Production and Validation of Neuraminidase Derived from Genotype 4 Reassortant Eurasian Avian-like H1N1 Virus as a Vaccine Candidate. Plants 2022, 11, 2984
Van et al. Bio-functional enhancement of plant based-haemagglutinin by fusion with IgMFc
CN121717881A (zh) 基于流感病毒骨架的优化SARS-CoV-2嵌合病毒样颗粒及应用
KR19990022028A (ko) 인플루엔자 헤마글루티닌 다가 백신의 제조방법
KR20150095300A (ko) M-세포 특이적 리간드 융합의 뎅기 바이러스 4가 에피토프 EDIII-Co1 합성 단백질 및 이의 용도

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240209